Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.236 EUR
−8.45 M EUR
102.00 K EUR
38.92 M
About CELYAD ONCOLOGY
Sector
Industry
CEO
Matthew R. Kane
Website
Headquarters
Mont-Saint-Guibert
Founded
2007
ISIN
BE0974260896
FIGI
BBG004NBYQW1
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CYAD is 0.714 EUR — it has decreased by −3.97% in the past 24 hours. Watch CELYAD ONCOLOGY stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange CELYAD ONCOLOGY stocks are traded under the ticker CYAD.
CYAD stock hasn't changed in a week, the month change is a 2.34% rise, over the last year CELYAD ONCOLOGY has showed a 85.45% increase.
CYAD reached its all-time high on May 25, 2015 with the price of 70.950 EUR, and its all-time low was 0.212 EUR and was reached on Aug 20, 2024. View more price dynamics on CYAD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYAD stock is 6.58% volatile and has beta coefficient of 0.23. Track CELYAD ONCOLOGY stock price on the chart and check out the list of the most volatile stocks — is CELYAD ONCOLOGY there?
Today CELYAD ONCOLOGY has the market capitalization of 29.04 M, it has increased by 2.67% over the last week.
Yes, you can track CELYAD ONCOLOGY financials in yearly and quarterly reports right on TradingView.
CELYAD ONCOLOGY is going to release the next earnings report on Apr 2, 2025. Keep track of upcoming events with our Earnings Calendar.
CYAD net income for the last half-year is −3.04 M EUR, while the previous report showed −4.71 M EUR of net income which accounts for 35.32% change. Track more CELYAD ONCOLOGY financial stats to get the full picture.
No, CYAD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 17.00 employees. See our rating of the largest employees — is CELYAD ONCOLOGY on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELYAD ONCOLOGY EBITDA is −7.44 M EUR, and current EBITDA margin is −9.61 K%. See more stats in CELYAD ONCOLOGY financial statements.
Like other stocks, CYAD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELYAD ONCOLOGY stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELYAD ONCOLOGY technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELYAD ONCOLOGY stock shows the buy signal. See more of CELYAD ONCOLOGY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.